isosorbide mononitrate

CLINICAL USE

Vasodilator:Treatment and prophylaxis of angina Adjunct in congestive heart failure

DOSE IN NORMAL RENAL FUNCTION

20–120 mg/day in divided doses

PHARMACOKINETICS

  • Molecular weight                           :191.1
  • %Protein binding                           :<4
  • %Excreted unchanged in urine     : 2
  • Volume of distribution (L/kg)       :0.6
  • half-life – normal/ESRD (hrs)      :1.5–5/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Dialysed. Dose as in normal renal function
  • HDF/high flux   :Dialysed. Dose as in normal renal function
  • CAV/VVHD      :Probably Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsSildenafil: hypotensive effect significantly enhanced – avoid concomitant useTadalafil: hypotensive effect significantly enhanced – avoid concomitant use

  • Vardenafil: hypotensive effect significantly enhanced – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Tolerance may develop. This may be minimised by having nitrate-‘free’ periodsisosorbide mononitrate.

  • Related News